



Correction to: early life ionizing radiation exposure and cancer risks: systematic review and meta-analysis

Kossi D. Abalo¹ · Estelle Rage¹ · Klervi Leuraud¹ · David B. Richardson² · Hubert Ducou Le Pointe³ · Dominique Laurier⁴ · Marie-Odile Bernier¹

Published online: 22 October 2020

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Correction to: *Pediatric Radiology* (2020)

<https://doi.org/10.1007/s00247-020-04803-0>

The original version of Table 2 included two incorrect values. The third line of the last column of Table 2 should read: 3.6 (0.5–12.0)^a. The fourth line of the last column of Table 2 should read: 2.3 (1.0–4.9)^b. The corrected table is included below.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s00247-020-04803-0>

✉ Kossi D. Abalo
kossi.abalo@irsn.fr

¹ Laboratory of Epidemiology, Institute for Radiological Protection and Nuclear Safety, BP 17, 92262 Fontenay-aux-Roses, France

² Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC, USA

³ Department of Pediatric Imaging, Hôpital d'Enfants Armand-Trousseau APHP, Paris, France

⁴ Research Department on Biological and Health Effects of Ionizing Radiation, Institute for Radiological Protection and Nuclear Safety, Fontenay-aux-Roses, France

Table 2 Cohort studies on postnatal medical ionizing radiation exposure and cancer risk

Study	Enrolled subject/cases	Period of inclusion	Age at inclusion (years)	Procedures	Outcomes	Doses (mGy)	Excess relative risk (95% CI) per 100 mGy
Hammer GP et al., 2011 [25], Germany	78,527/68	1976–2003	<14.5	X-ray	- All cancer - Leukemia and lymphoma	—	0.97 (0.75–1.23) ^s 1.05 (0.74–1.45) ^s
Pearce MS et al., 2012 [30], UK	178,604/74 176,587/135	1985–2002 1986–2002	0–22 0–22	CT	- Leukemia - Brain tumors	RBM: 2.32 to 51.13 Brain: 0.25 to 104.16	3.6 (0.5–12.0) ^a 2.3 (1.0–4.9) ^b
Mathews JD et al., 2013 [45], Australia	Exposed: 680,211/3,150 Unexposed: 10,261,420/57,524	1985–2005	0–19	CT	- All cancer ^c - Lymphoma and hematopoietic - Brain tumors	RBM: 5.9 ^m Brain: 49 ^m	3.5 (2.6–4.2) ^d 3.9 (1.4–7.0) ^a 2.1 (1.4–29.0) ^b
Huang WY et al., 2014 [46], Taiwan	Exposed: 24,418/39 Unexposed: 97,668/122	1998–2006	<18	CT	- All-cancer - Leukemia - Brain tumors	—	1.29 (0.90–1.85) ^h ^a 1.90 (0.82–4.40) ^h ^a 2.56 (1.44–4.54) ^h ^a
Liao YH et al., 2014 [47], Taiwan	Exposed: 31,908/52 Unexposed: 127,632/99	1997–2008	1–18	Cystourethrography	- Genital cancer - Urinary system cancer - Hematologic system	—	6.19 (1.37–28.00) ^h 5.80 (1.54–21.90) ^h 1.82 (1.05–3.13) ^h
White IK et al., 2014 [48], USA	104/0	1991–2001	0–6	CT	- All cancer - Leukemia	—	—
Krille L et al., 2015 [49], Germany	39,184/38	1980–2010	<15	CT	- Brain tumors - All-cancer - Leukemia - Brain tumors	RBM: 11.7 ^m Brain: 34.4 ^m	-1.4 (-5.6–3.0) ^a 0.9 (-1.9–3.7) ^a 0.8 (0.4–1.3) ^a
Journy N et al., 2016 [28], France	67,274/106	2000–2010	<10	CT	- Leukemia - Lymphoma - Brain tumors	RBM: 8.9 (10.7) ^{m(sd)} Brain: 23.1 (31.8) ^{m(sd)}	5.7 (-7.9–19.3) 1.8 (-6.8–10.4) 2.2 (-1.6–6.1)
Meulenpas JM et al., 2018 [50], The Netherlands	168,394/454	1979–2012	<18	CT	- Leukemia - Brain tumors	RBM: 9.5 (2.0–11.8) ^{m(IQR)} Brain: 38.5 (1.5–49.4) ^{m(IQR)}	0.21 (-0.12–2.40) ^a 0.86 (0.20–2.22) ^b
Harbron RW, 2018 [51], UK	11,270/41	—	<22	Cardiac catheterization and CT	- Lymphohaematopoietic neoplasia	RBM: 8.8 (16.5) ^{m(IQR)}	54.1 (10.4–180.7) ^{a,c} 1.8 (-0.2–9.6) ^{a,f}

CI confidence interval, *h* hazard ratio, *IQR* interquartile range, *m* mean, *RBM* red bone marrow, *s* standardized incidence ratio, *sd* standard deviation.

^a Exclusion period 2 years

^b Exclusion period 5 years

^c Exclusion period 1 year

^d Per 100 mSv

^e Excess relative risk (ERR) for the whole population

^f ERR after exclusion of patients with transplants